Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026

▤ Summary

Rznomics shared interim Phase 1/2a data for its RNA editing-based gene therapy RZ-001 at ASNO 2026. The company reported a manageable safety profile with no dose-limiting toxicity and no treatment-related Grade 4 or higher adverse events. Several patients showed prolonged disease control and tumor recurrence inhibition beyond six months, which supports continued enrollment and follow-up. The company is also advancing RZ-001 in hepatocellular carcinoma and recently received FDA RMAT designation for that program.

▦ Linked Companies